Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to ...

At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands ...

A new spatial transcriptomic technology captures RNA patterns without requiring expensive imaging ...

A new software tool, ovrlpy, improves quality control in spatial transcriptomics, a key technology in biomedical research. Developed by the Berlin Institute of Health at Charité (BIH) in international ...

Researchers have installed a high-resolution 3D spatial multi-omics system to study RNA regulation in intact brain tissue, ...

Researchers launched external beta testing of a 3D spatial transcriptomics system that maps intact tumors in three dimensions and enabling single-cell resolution.

Applying single-cell RNA sequencing has led researchers to be able to profile the entire transcriptome of cells. However, these transcriptomes prove difficult to link back to their original location ...

"Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina. "Illumina spatial ...